Cognitive impairment remains a major complication of advanced human immunodeficiency virus (HIV) infection despite the widespread use of anti-retroviral therapy. Diagnosis is made by exclusion making biomarkers of great potential use. Thus, we used an integrated proteomics platform to assess cerebrospinal fluid protein profiles from 50 HIV-1 seropositive Hispanic women. Nine of 38 proteins identified were unique in those patients with cognitive impairment (CI). These proteins were linked to cell signaling, structural function, and antioxidant activities. This work highlights, in a preliminary manner, the utility of proteomic profiling for biomarker discovery for HIV-1 associated cognitive dysfunction. Published by Elsevier B.V.
Introduction
Cognitive, behavioral, and motor dysfunction induced as a consequence of HIV-1 infection remain chronic and debilitating despite the advent of anti-retroviral therapy (McArthur, 2004) .
In its most severe form, HIV-associated cognitive impairment is termed HIV-associated dementia (HAD). Anti-retroviral therapy has altered the magnitude of HIV-associated cognitive impairments as patients present milder forms of disease and show different patterns of mental dysfunction. This represents significant challenges in making a firm diagnosis to the exclusion of opportunistic brain infections, tumors, or psychiatric and behavioral disorders (Everall et al., 2005; Wojna and Nath, 2006; Ances and Ellis, 2007) . In era of active antiretroviral therapy, the term HIV-associated cognitive impairment (CI) is preferred over HAD. Indeed, cognitive dysfunction is manifest with milder forms of impairment and present with increased CD4 + T cell counts (Navia and Rostasy, 2005; Wojna et al., 2006; Woods et al., 2007) .
